Explore

Trendline Trendline
Eli Lilly's Base Editing Therapy Shows Promise in Lowering Cholesterol

Eli Lilly's Base Editing Therapy Shows Promise in Lowering Cholesterol

Eli Lilly's Base Editing Therapy Shows Promise in Lowering Cholesterol
Rapid Read Rapid Read
Gene-Editing Drug VERVE-102 Shows Promise in Reducing Bad Cholesterol

Gene-Editing Drug VERVE-102 Shows Promise in Reducing Bad Cholesterol

A Phase I clinical trial of an experimental gene-editing drug, VERVE-102, has shown promising results in reducing bad cholesterol levels. The trial involved 35 participants and demonstrated a 62% reduction in low-density lipoprotein (LDL) cholesterol after a single dose. The drug uses mRNA-based gene-editing technology to target liver cells, which are crucial in cholesterol metabolism. The trial reported no serious adverse events, although a mild increase in liver enzymes was observed, indicating minor liver injury. The results, published in the New England Journal of Medicine, suggest that VERVE-102 could significantly lower the risk of cardiovascular disease if the effects are sustained over time.
Trendline Trendline
Phanes Therapeutics Reports Positive Phase 2 Results for Spevatamig in Metastatic Pancreatic Cancer Treatment

Phanes Therapeutics Reports Positive Phase 2 Results for Spevatamig in Metastatic Pancreatic Cancer Treatment

Phanes Therapeutics Reports Positive Phase 2 Results for Spevatamig in Metastatic Pancreatic Cancer Treatment
Trendline Trendline
PanTher Therapeutics Advances Pancreatic Cancer Treatment with PTM-101, Appoints New Board Member

PanTher Therapeutics Advances Pancreatic Cancer Treatment with PTM-101, Appoints New Board Member

PanTher Therapeutics Advances Pancreatic Cancer Treatment with PTM-101, Appoints New Board Member
Trendline Trendline
Solu Therapeutics Receives FDA Fast Track Designation for STX-0712 in Leukemia Treatment

Solu Therapeutics Receives FDA Fast Track Designation for STX-0712 in Leukemia Treatment

Solu Therapeutics Receives FDA Fast Track Designation for STX-0712 in Leukemia Treatment
Trendline Trendline
FDA Initiates Priority Review for Sanofi's Gaucher Disease Drug Venglustat

FDA Initiates Priority Review for Sanofi's Gaucher Disease Drug Venglustat

FDA Initiates Priority Review for Sanofi's Gaucher Disease Drug Venglustat
Rapid Read Rapid Read
FDA Approves Brenus Pharma's IND Application for STC-1010 in Metastatic Colorectal Cancer

FDA Approves Brenus Pharma's IND Application for STC-1010 in Metastatic Colorectal Cancer

Brenus Pharma, a biotechnology company specializing in immuno-oncology, has received approval from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for STC-1010. This drug is designed to treat microsatellite stable (MSS) metastatic colorectal cancer (mCRC), a condition affecting approximately 95% of mCRC patients who typically show minimal response to standard immunotherapies. The FDA's approval allows Brenus Pharma to proceed with clinical evaluations in the U.S. under the BreAK-CRC001 study. This development follows European regulatory approvals and initial positive results from early Phase Ia trials. The company plans to present further data at the ESMO annual congress in 2026.
Trendline Trendline
Brenus Pharma's Immunotherapy for Colorectal Cancer Receives FDA IND Approval

Brenus Pharma's Immunotherapy for Colorectal Cancer Receives FDA IND Approval

Brenus Pharma's Immunotherapy for Colorectal Cancer Receives FDA IND Approval
Trendline Trendline
Eli Lilly Advances Gene Therapy for Cholesterol Reduction with VERVE-102

Eli Lilly Advances Gene Therapy for Cholesterol Reduction with VERVE-102

Eli Lilly Advances Gene Therapy for Cholesterol Reduction with VERVE-102
Trendline Trendline
Nielsen BioSciences Completes Successful Phase 3 Trial for CANDIN in Wart Treatment

Nielsen BioSciences Completes Successful Phase 3 Trial for CANDIN in Wart Treatment

Nielsen BioSciences Completes Successful Phase 3 Trial for CANDIN in Wart Treatment
Trendline Trendline
Solu Therapeutics Receives FDA Fast Track Designation for STX-0712 Targeting Chronic Myelomonocytic Leukemia

Solu Therapeutics Receives FDA Fast Track Designation for STX-0712 Targeting Chronic Myelomonocytic Leukemia

Solu Therapeutics Receives FDA Fast Track Designation for STX-0712 Targeting Chronic Myelomonocytic Leukemia
Rapid Read Rapid Read
Emalex Biosciences Seeks FDA Approval for Ecopipam to Treat Tourette Syndrome in Children

Emalex Biosciences Seeks FDA Approval for Ecopipam to Treat Tourette Syndrome in Children

Emalex Biosciences is preparing to seek approval from the U.S. Food and Drug Administration (FDA) for ecopipam, a drug designed to treat children with motor and vocal tics caused by Tourette syndrome (TS). This follows a successful phase III clinical trial led by Dr. Donald Gilbert at Cincinnati Children's Hospital, which demonstrated that ecopipam can significantly reduce the risk of tic relapse in children. Unlike existing FDA-approved treatments for TS, which are antipsychotics initially approved for schizophrenia, ecopipam targets the dopamine D1 receptor, potentially offering fewer side effects. The trial involved 216 participants, with results showing a 50% reduction in relapse risk for those continuing ecopipam compared to a placebo.